First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors

Summary

This clinical trial is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy signals of DS1025a, given as a single agent to participants with advanced, metastatic, or unresectable solid tumors.

Timeline

Start

2026-08-03

Primary completion

2028-01-21

Completion

2029-01-21

Drugs

Indications